Emerging Growth News
EIGER: A Small Cap Biotech With A Billion Dollar Hepatitis Drug
|
EIGER completed a reverse merger into publicly-traded Celladon on March 22 and concluded a concurrent $39.5 million capital raise. On August 18th ... ...read more
Growth Capitalist (https://growthcapitalist.com/author/bgoets/page/27/)
EIGER completed a reverse merger into publicly-traded Celladon on March 22 and concluded a concurrent $39.5 million capital raise. On August 18th ... ...read more
If the drug can pick up an FDA approval, and we're pretty certain this is the motive behind the merger – in essence, it's basically a reverse merger to ... ...read more
... advantageous to a buyer because of tax reasons, but it is reduced pursuant to Pfizer's (NYSE:PFE) failed reverse merger with Allergan (NYSE:AGN). ...read more
A reverse merger is the acquisition of a public company, usually a dormant shell (i.e., has no or nominal business operations or noncash assets for an ... ...read more